medigraphic.com
ISSN 1561-297X (Print)

2015, Number 4

<< Back Next >>

Rev Cubana Estomatol 2015; 52 (4)

Efficacy of combined radiotherapy and chemotherapy versus radiotherapy for oral squamous cell carcinoma

Irisarri AJ, Oliva MP

Language: English
References: 22
Page: 52-58
PDF size: 286.62 Kb.


ABSTRACT

Introduction: in the last decade, with all the advanced medical research in the treatments for cancer, there is a constant debate for the best possible treatment for oral squamous cell carcinomas. Radiotherapy with surgery has they compared with the addition of chemotherapy for control of the disease or survival of the patient. Objective: to compare the effectiveness of radiotherapy with combined chemotherapy and radiotherapy for the control of oral squamous cell carcinomas. Methods: it was a systematic review with meta-analysis. Randomized trials in all phases were search with specific inclusion criteria through electronic database, hand searching and contacting experts in the field. After exclusion, criteria and the use of critical review checklist, three trials they selected for analysis. Three randomized trials representing 508 patients they identified. Some trials they analyzed in Review manager software 5.0®. The fix effect model they chosen for the statistical analysis, assuming that any observed variation in the score was an error of the specific article, with a confidence of 95% (CI 1.13–2.77). The I2 presents percent of heterogeneity of 0%, indicating that there is no clinically significant change in the results of the studies included. Result: evidenced the significance of 0.44 (higher than 0.05) in the chi square test indicating that the results are homogeneous or clinically similar. The Forest plot is located in the experimental group (chemotherapy and radiotherapy), establishing the clinical recommendation of use. Conclusion: the usage of chemotherapy treatment in combination of radiotherapy regimen they recommended as for its promising results. Not also, the overall survival has improved, survival and distant metastasis free rates improve.


REFERENCES

  1. Sapp J, Eversole L, Wysocki G. Patología oral y maxilofacial contemporánea. 2° edicion. España: Elsevier; 2005.

  2. Huang S, O'Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18(2):233-40.

  3. Inohara H, Takenaka Y, Yoshii T, Nakahara S, Yamamoto Y, Tomiyama Y, Seo Y, Isohashi F, Suzuki O, Yoshioka Y, Sumida I, Ogawa K. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV. Squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015;91(5):934-41.

  4. Chagas F, Silva B, micrographic surgery: a study of 83 cases. Anais Brasileiros de Dermatologia. 2012;87(2):228-34.

  5. Smee R, Broadley K, Bridger G, Williams J. Floor of mouth carcinoma: Surgery still the dominant mode of treatment. Journal of Medical Imaging and Radiation Oncology. 2012;56(3):338-46.

  6. White S, Pharoah M. Radiologia oral, principios e interpretación. 4° ed. Editorial Harcourt; 2001.

  7. Kovács A, Turowski B. Multimodality Treatment Including Postoperative Radiation and Concurrent Chemotherapy with Weekly Docetaxel is Feasible and Effective in Patients with Oral and Oropharyngeal Cancer. Strahlenther Onkol. 2005;181:26-34.

  8. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial. J Clin Oncol. 2000;18(7):1458-64.

  9. Merlano, M. Benasso M, Corvò R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G,Bonelli L, Santi L. Five-Year Update of a Randomized Trial of Alternating Radiotherapy and Chemotherapy Compared With Radiotherapy Alone in Treatment of Unresectable Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst. 1996;88(9):583.

  10. Wee J, Tan E, Tai B. Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American JoiInternational Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety. J Clin Oncol. 2005;23:6730-8.

  11. Altman D, Higgins J, Thompson S, Deeks J. Measuring inconsistency in metanalysis. BMJ. 2003;327(7414):557-60.

  12. Higgins J, Green S. The Cochrane Library Volume 4. Chichester, UK: Cochrane Handbook for Systematic Reviews of Interventions; 2006.

  13. Curran D, Giralt J, Harari P, Kian K, Roger B. Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab. J Clin Oncol. 2007;25:2191-7.

  14. Nair V, Maeda L, Loannidis J. Clinical outcome prediction by microRNAs in human cancer: a systematic review. Natl Cancer Inst. 2012;104(7):528-40.

  15. Li, X. Ma, Zhang, Huang, Liu, Wei Y. Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis Dis Markers 2014;12(123):106-97.

  16. Babji D, Kale A, Hallikerimath S, Kotrashetti V. Histomorphometric study to compare histological changes between oral squamous cell carcinoma and apparently normal adjacent oral mucosa. Indian J Otolaryngol Head Neck Surg. 2015;67(1):21-8.

  17. Santos M, Servato J, Cardoso S, de Faria P, Eisenberg A, Dias F, Loyola A. Squamous cell carcinoma at maxillary sinus: clinicopathologic data in a single Brazilian institution with review of literature. Int J Clin. 2014;7(12):8823-32.

  18. Akhlaghi F, Esmaeelinejad M, Shams A, Augend A. Evaluation of neo-adjuvant, concurrent and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma: a meta-analysis. J Dent (Tehran). 2014;11(3):290-301.

  19. Soares J, Cançado H, Sousa A, Moraes G, Carvalho J, Silva G, Porcaro-Salles J. Prognostic factors for surgically resected squamous cell carcinoma of the lower oral cavity. Minerva Stomatol. 2014;63(10):341-9.

  20. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke K, Ghadjar P. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2015;91(5):916-24.

  21. Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol. 2015;75(4):821-7.

  22. Shenouda G, Zhang Q, Ang KK, Machtay M, Parliament MB, et al. Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015;91(5):907-15.




2020     |     www.medigraphic.com